美多芭联合普拉克索对帕金森病的临床疗效及安全性研究

doi:10.3969/j.issn.1006-6233.2018.11.035

摘要
图/表
参考文献
相关文章 (5)

全文: PDF (1252 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 研究帕金森病患者治疗中美多芭联合普拉克索对临床疗效及安全性影响。方法: 选取2015年5月至2017年3月帕金森病患者95例,随机数字表法分为对照组(n=42例)和研究组(n=53例)。对照组患者给予美多芭治疗,研究组患者给予美多芭联合普拉克索治疗。比较两组患者治疗前后UPDRS Ⅱ、UPDRS Ⅲ及UPDRS Ⅳ评分,治疗优良率及治疗过程中不良反应发生情况。结果: 两组患者UPDRS Ⅱ、UPDRS Ⅲ及UPDRS Ⅳ评分对比均无统计学差异(P>0.05),研究组患者治疗后第8周、12周的UPDRS Ⅱ及UPDRS Ⅲ评分均明显低于对照组,两组患者治疗后第12周各项评分均明显低于各自治疗后第8周,两组患者治疗后第8周、第12周各项评分较各自治疗前均明显下降,且均具有统计学差异(P<0.05)。对照组患者治疗优良率为59.52%,显著低于研究组患者的优良率88.68%,有统计学差异(χ²=4.504,P<0.05)。对照组不良反应发生率为23.81%显著高于研究组不良反应发生率7.55%,有统计学差异(χ²=5.309,P<0.05)。结论: 帕金森病患者治疗中美多芭联合普拉克索可提高临床疗效,有利于改善患者日常生活能力和运动功能,且具有较高的安全性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈丹

关键词 ：帕金森, 美多芭, 普拉克索, 优良率, 运动功能能力

Abstract：Objective: To study the effect of treatment with midazolam and pramipexole on clinical efficacy and safety in patients with Parkinson's disease. Methods: A total of 95 patients with Parkinson's disease treated in our department from May 2015 to March 2017 were selected. The random number table was divided into control group (n=42) and study group (n=53). Patients in the control group were treated with metoprolol, and patients in the study group were treated with metopa and pramipexole. The UPDRS II, UPDRS III, and UPDRS IV scores before and after treatment were compared between the two groups of patients, and the excellent rate of treatment and the occurrence of adverse reactions during treatment were compared. Results: There was no significant difference in the UPDRS II, UPDRS III, and UPDRS IV scores between the two groups (P>0.05). The UPDRS II and UPDRS III scores at the 8th and 12th week after treatment were significantly lower in the study group than in the control group. The scores at the 12th week after treatment in both groups were significantly lower than those at the 8th week after treatment. The scores at the 8th and 12th week after treatment were significantly lower than those before treatment in both groups and were statistically significant. Difference (P<0.05). The rate of excellent treatment in the control group was 59.52%, which was significantly lower than that in the study group (88.68%). There was a statistically significant difference (χ²=4.504, P<0.05). The incidence of adverse reactions in the control group was significantly higher than that in the study group (23.81%), which was 7.55%, with statistical significance (χ²=5.309, P<0.05). Conclusions: The treatment of Parkinson's disease patients with midazolam combined with pramipexole can improve the clinical curative effect, which is beneficial to improve the daily living ability and motor function of patients, and has a higher safety.

Key words： Parkinson Madopar Praxaline Good rate Motor function

基金资助:辽宁省科技科技攻关计划项目,(编号:20144752816)

引用本文:

陈丹. 美多芭联合普拉克索对帕金森病的临床疗效及安全性研究[J]. 河北医学, 2018, 24(11): 1903-1905.
CHEN Dan. Analysis of Clinical Efficacy and Safety of Patients with Parkinson's Disease Treated with Metoprolol and Pramipexole. HeBei Med, 2018, 24(11): 1903-1905.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.11.035 或 http://www.hbyxzzs.cn/CN/Y2018/V24/I11/1903